Why Inhibrx's Recent Strength May Not Be Built to Last

Inhibrx (NASDAQ:INBX) has staged a sharp rally after reporting positive topline results from its registrational trial of Ozekibart (INBRX-109) back in October 2025. The stock surged more than 150% in a short span, drawing significant investor attention. However, when the move is examined through the lens of the Adhishthana framework, a structural risk begins to surface, particularly when analysing the stock's positioning on the monthly cycle.Analysing Inhibrx's Monthly StructureInhibrx is currently in Phase ...